
AGMB Stock Forecast & Price Target
AGMB Analyst Ratings
Bulls say
AgomAb Therapeutics is compelling because ontunisertib has already shown a clean, GI-restricted safety profile in Phase 2a STENOVA, with no cardiac toxicity signal, balanced adverse events versus placebo, and objective signs of anti-fibrotic activity including a 31.8% reduction in non-passable strictures at 200 mg BID. The company also addresses a large unmet need in FSCD, where about ~143K U.S. patients are estimated to be clinically actionable and there are no approved therapies, while the planned 24-week Ph2b NOV-ERA in ~320 patients and the full OLE data in 2H26 offer clear catalysts to validate durability and registrational potential. AGMB’s second asset, AGMB-447, adds upside optionality in IPF, supported by two Phase 1 studies showing lung-restricted exposure, strong ALK5 target engagement, and clean systemic safety, while pro forma cash of approximately €275M supports operations into 1H29.
Bears say
AgomAb Therapeutics is a high-risk clinical-stage biopharmaceutical company with no approved products, making its valuation heavily dependent on early data from ontunisertib and AGMB-447 that may not translate into later clinical success or regulatory approval. Its reliance on a narrow ALK5/TGFβR1 strategy also creates concentration risk, since any safety signal from chronic ALK5 inhibition could impair both lead programs and weaken confidence in the broader pipeline. Financially, about €285M of pro forma cash appears insufficient for sustained development through clinical and preclinical work, raising dilution and financing risk, while reliance on CMOs and competition in FSCD add further execution pressure.
This aggregate rating is based on analysts' research of AgomAb Therapeutics SA and is not a guaranteed prediction by Public.com or investment advice.
AGMB Analyst Forecast & Price Prediction
Start investing in AGMB
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About AgomAb Therapeutics SA (AGMB) Forecast
AGMB Analyst Forecast & Price Prediction
Start investing in AGMB
Order type
Buy in
Order amount
Est. shares
0 shares